Form 4: Intuitive Surgical Executive Robert DeSantis Executes Stock Option Sales Under 10b5-1 Plan

EVP & Chief Strategy & Corp Op of Intuitive Surgical, Robert DeSantis, reports the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Summary

• Robert DeSantis, EVP & Chief Strategy & Corp Op at Intuitive Surgical Inc. (ISRG), executed multiple transactions involving common stock on May 28 and May 29, 2024.
• These transactions involved the exercise of non-qualified stock options and the subsequent sale of common stock.
• The sales were conducted under a pre-arranged trading plan (Rule 10b5-1) set to expire on December 9, 2024.
• On May 28, 2024, DeSantis exercised options to acquire 188 shares at $290.33, 198 shares at $347.4167, and 198 shares at $245.6, then sold 188 shares at $404.41, 198 shares at $404.41 and 198 shares at $404.41.
• On May 29, 2024, DeSantis exercised options to acquire 188 shares at $208.9 and sold 188 shares at $396.59.
• Following these transactions, DeSantis directly owns 5,506 shares of common stock.
• He also holds derivative securities including non-qualified stock options to purchase additional shares at various exercise prices and expiration dates.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction under a pre-existing plan. There's no indication of positive or negative news about the company.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Future Outlook

The executive will continue to execute trades under the 10b5-1 plan until its expiration on December 9, 2024.

Industry Context

Insider transactions are common in publicly traded companies and are closely monitored by regulators and investors. The use of a 10b5-1 plan indicates a pre-arranged strategy for selling shares, which can mitigate concerns about opportunistic trading based on inside information.

Comparison to Industry Standards

• Executive compensation packages in the medical device industry often include stock options as a significant component.
• Trading activity by executives is a normal occurrence, but the use of 10b5-1 plans is considered a best practice for ensuring transparency and compliance.
• Companies like Medtronic, Stryker, and Johnson & Johnson also see regular Form 4 filings from their executives related to stock option exercises and sales.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-defined trading plan and do not reflect a change in the executive's long-term outlook for the company.

Key Dates